Role of ctDNA in predicting the outcome of patients with hormone receptor–positive, HER2-negative advanced breast cancer treated with first-line ribociclib and letrozole: BioItaLEE trial

Pretreatment and early dynamics of ctDNA represent promising prognostic and predictive biomarkers in patients with HR+/HER2- ABC treated with ribociclib/letrozole. Early ctDNA dynamic appeared a promising surrogate biomarker for treatment. Further studies are warranted to validate their clinical utility.

Authors

Institutions

Publication Details

Journal
Clinical Cancer Research
Published
2026-01-26
DOI
https://doi.org/10.1158/1078-0432.ccr-25-0650
Primary Topic
Advanced Breast Cancer Therapies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Role of ctDNA in predicting the outcome of patients with hormone receptor–positive, HER2-negative advanced breast cancer treated with first-line ribociclib and letrozole: BioItaLEE trial

G. Allegrini, Maria Rosaria Valerio, Giulia Bianchi, C. Zamagni et al.
Clinical Cancer Research
Advanced Breast Cancer Therapies
article

Role of ctDNA in predicting the outcome of patients with hormone receptor–positive, HER2-negative advanced breast cancer treated with first-line ribociclib and letrozole: BioItaLEE trial

G. Allegrini, Maria Rosaria Valerio, Giulia Bianchi, C. Zamagni, Diletta Valsecchi, Matteo Benelli, Michele Orditura, Daniela Castelletti, Nicola Fenderico, Valentina Guarneri, Maurizio Callari, V. Adamo, S. Tamberi, Donatella Grasso, Lucia Del Mastro, Emanuela Romagnoli, Luca Malorni, Saverio Cinieri, Ida Paris, Grazia Arpino, Alberto Zambelli, Roberta Caputo, Filippo Montemurro, Giampaolo Bianchini, Marina E. Cazzaniga, Marco Colleoni, Michelino De Laurentiis
article en

Abstract

Pretreatment and early dynamics of ctDNA represent promising prognostic and predictive biomarkers in patients with HR+/HER2- ABC treated with ribociclib/letrozole. Early ctDNA dynamic appeared a promising surrogate biomarker for treatment. Further studies are warranted to validate their clinical utility.

Clinical Cancer Research
University of Udine (IT), Regione Campania (IT), Agostino Gemelli University Polyclinic (IT), IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola (IT), Fondazione Michelangelo (IT), Ospedale A. Perrino (IT), Ospedale Papa Giovanni XXIII (IT), Istituto Oncologico Veneto (IT), Presidio Ospedaliero (IT), Ospedale per gli Infermi (IT), IRCCS Ospedale San Raffaele (IT), Novartis (Italy) (IT), Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT), University of Teacher Education Zug (CH), Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo (IT), Ospedale di Livorno (IT), Candiolo Cancer Institute (IT), Fondazione IRCCS Istituto Nazionale dei Tumori (IT), Azienda Ospedaliera Ospedali Riuniti Papardo Piemonte (IT), Hospital of Prato (IT), University of Florence (IT), European Institute of Oncology (IT), University of Milano-Bicocca (IT), University of Naples Federico II (IT), University of Genoa (IT)
Good health and well-being
Openalex Percentile: Top 78%
Advanced Breast Cancer Therapies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.